Oct 29 (Reuters) – Cerenome, Inc: * CERENOME COMPLETES ENROLLMENT IN PHASE 2 RESPECT-GBM TRIAL OF REYOBIQ™ IN RECURRENT GLIOBLASTOMA * CERENOME – EXPECTS TOPLINE PHASE 2 RESPECT-GBM DATA IN MID-2027
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
* Investors digest inflation report * Data shows US economy grew faster than expected in…
VIDEO SHOWS: DAY FOUR OF THE PAN PACIFIC OPEN - A WTA 500 TOURNAMENT IN…
WASHINGTON, Oct 29 (Reuters) - The number of Americans filing new claims for unemployment benefits…
By Raphael Satter, AJ Vicens and Phil Stewart WASHINGTON, Oct 29 (Reuters) - The Pentagon…
Oct 29 (Reuters) - Xiamen Xiangyu Co Ltd: * Q3 NET PROFIT DOWN 0.77% Y/Y…
New Delhi [India], October 29: Maxwell Engineering Solutions Limited (“Maxwell” or “the Company”), a precision…